Effect of Trimetazidine on the Improvement of Coronary Microvascular Dysfunction in Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease)

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03504202

Acronym

T-MICRO

Enrollment

Registered

2018-04-20

Start date

2019-03-01

Completion date

2020-09-01

Last updated

2018-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease) Who Have Coronary Microvascular Dysfunction

Brief summary

This is a prospective study which aims to explore the effect of Trimetazidine on the improvement of coronary microvascular dysfunction in patients with INOCA (ischemia and no obstructive coronary artery disease). Enrolled patients will be assessed SAQ(Seattle Angina Score), Canadian Angina Grade(Canadian Cardiovascular Society, CCS), Six-Minute Walk Test, CFR(coronary flow reserve) .CFR inspection with D-SPECT and pressure guide wire.Patients will receive six months Trimetazidine(35mg tid) after enrollment. And their SAQ (Seattle Angina Score), Canadian Angina Grade(Canadian Cardiovascular Society, CCS), Six-Minute Walk Test, CFR will be followed up.

Interventions

DRUGTrimetazidine

After enrollment, experimental group will receive Trimetazidine(35mg tid) for six months .

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age≥18 years * Typical angina symptoms * Coronary angiography or coronary computed tomography examination showed no significant epicardial coronary artery stenosis (\<20%) * Never used trimetazidine * The CFR measured by the pressure guide wire is less than 2.0 * agree to participant the study and sign informed written consent * available for six months follow up

Exclusion criteria

* Severe liver and kidney disease * Contraindications of Trimetazidine * Use of CYP3A inhibitors, such as diltiazem, verapamil, and other drugs that may affect CFR measurements * QT interval extension * Atrial fibrillation or left bundle branch block * Left ventricular systolic dysfunction (EF \<55%) * Coronary artery fistula * Myocardial bridge * Non-cardiogenic chest pain and other heart diseases * Severe heart valve disease * Diabetes * Recent ACS( Acute coronary syndrome) * Pregnancy * Failed to complete inspection

Design outcomes

Primary

Measure	Time frame
Coronary flow reserve (CFR) improves	six months

Secondary

Measure	Time frame
Seattle angina score or Canadian angina grade drops	six months
Six-minute walking experiment improves	six months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026